The Latest Breaking News from FDA

A broader market rally is a reason to be bullish long term, but the Fed meeting is one reason to be cautious now. Biogen jumped late Friday. Watch Tesla and Nvidia.

Leqembi could become the first treatment of its kind to receive traditional approval from the FDA.

Staff will be left at risk if proposals to ban members under police investigation from Westminster estate dropped, unions say

Biohacking promises to make you feel and look decades younger. So what's the catch?

Biogen stock rose Wednesday after the FDA posted documents that suggest the agency will approve Alzheimer's treatment Leqembi.

With the growing prevalence of chronic diseases, the adoption of advanced digital technologies, and new drug discoveries, the pharmaceutical industry is set to witness significant growth this year and beyond. Thus, it could be wise to invest in quality pharma stocks Ipsen (IPSEY), Supernus (SUPN), and Kamada (KMDA), which are…

With vaccines on the horizon, RSV could finally be preventable. But anti-vax misinfo could get in the way

Powerful new artificial intelligence tools can perpetuate long-standing racial inequities if they are not designed very carefully. Researchers and regulators are taking note, but perils are vast.

TikTokers are using the dietary supplement berberine, calling it "nature's Ozempic" as a weight-loss drug that's cheaper and easier to attain.